Atkins MB et al. Long-term PFS from TIVO-3: Tivozanib (TIVO) versus sorafenib (SOR) in relapsed/refractory (R/R) advanced RCC. ASCO GU 2022;Abstract 362.

Cella D et al. The relationship between health-related quality of life (HRQoL) and Clinical outcomes in patients with advanced renal cell carcinoma (aRCC) in CheckMate (CM) 214. ASCO 2022;Abstract 4502.

Choueiri TK et al. Inhibition of hypoxia-inducible factor-2alpha in renal cell carcinoma with belzutifan: A phase 1 trial and biomarker analysis. Nat Med 2021;27(5):802-5. Abstract

Choueiri TK et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2021;384(9):829-41. Abstract

Choueiri TK et al. Pembrolizumab vs placebo as adjuvant therapy for patients with renal cell carcinoma: Patient-reported outcomes (PRO) in KEYNOTE-564. ESMO 2021;Abstract 6530.

Jonasch E et al. Belzutifan for renal cell carcinoma in von Hippel-Lindau disease. N Eng J Med 2021;385(22):2036-46. Abstract

Motzer R et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 2021;384(14):1289-300. Abstract

Motzer RJ et al.  Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). ESMO 2021;Abstract 661P.

Motzer RJ et al. Final overall survival and molecular analysis of IMmotion151, a phase 3 trial comparing atezolizumab plus bevacizumab vs sunitinib in patients with previously untreated metastatic renal cell carcinoma. JAMA Oncol 2022;8(2):275-80. Abstract

Powles T et al. CALYPSO: A three-arm randomized phase II study of durvalumab alone or with savolitinib or tremelimumab in previously treated advanced clear cell renal cancer. ASCO 2022;Abstract LBA4503.

Rini BI et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426. ASCO 2021;Abstract 4500.

Rini BI et al. Prospective cardiovascular surveillance of immune checkpoint inhibitor-based combination therapy in patients with advanced renal cell cancer: Data from the phase III JAVELIN renal 101 trial. J Clin Oncol 2022;[Online ahead of print]. Abstract

Rini BI et al. TIVO-3: Tivozanib in patients with advanced renal cell carcinoma (aRCC) who have progressed after treatment with axitinib. ASCO GU 2021;Abstract 278.

Ryan CW et al. EVEREST: Everolimus for renal cancer ensuing surgical therapy — A phase III study (SWOG S0931, NCT01120249). ASCO 2022;Abstract LBA4500.

Suárez C et al. Association between depth of response (DepOR) and clinical outcomes: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 9ER. ASCO 2022;Abstract 4501.